FDA OK's Paige's FullFocus viewer

By LabPulse.com staff writers

July 21, 2020 -- Artificial intelligence (AI) pathology company Paige has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its FullFocus viewer for primary diagnosis of digital pathology slides.

The FullFocus viewer allows pathologists to view and navigate images from all major commercial brands of scanners, but this clearance initially applies to FullFocus when used together with the Philips Ultra Fast scanner.

In November 2019, FullFocus received the CE Mark, opening its use in European markets. Paige has early access trials underway across the U.S., Europe, and Brazil. The firm is also working to expand upon the 510(k) clearance to include the use of FullFocus with additional scanners and monitors in the near future.

Person evaluating pathology image on screen
Image courtesy of Paige.
Paige raises $15M more for AI, cancer pathology
Artificial intelligence (AI) pathology company Paige has raised $15 million in additional funding from Goldman Sachs to support its efforts related...
Paige raises additional funds for AI, cancer pathology
Artificial intelligence (AI) pathology company Paige has raised additional funding from Goldman Sachs to support its efforts related to cancer diagnostics...
Clinical diagnostics and the artificial intelligence boom
Artificial intelligence (AI) is becoming increasingly common in our everyday lives, but the role of AI in clinical diagnostics is the subject of intense...
Paige raises $45M, vows deeper dive into AI, cancer pathology
Artificial intelligence (AI) pathology company Paige has raised $45 million in a series B round and said it plans to use the cash to expand its portfolio,...
Philips, Paige join forces on AI and digital pathology
Philips Healthcare and Paige are joining to deliver artificial intelligence (AI) applications for cancer to pathology laboratories.

Copyright © 2020 LabPulse.com

Last Updated np 7/20/2020 10:17:08 AM